Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Yushuda Tablet for mild to moderate major depressive disorder
ChiCTR2200065191Phase 3Completed
- Sponsor
- Shanghai Mental Health Center
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Yushuda in major depressive disorder (MDD) (2 arms), sponsored by Shanghai Mental Health Center. Primary endpoint: Reduction in HAMD-17 total score from baseline after 8 weeks. Started Apr 2022; status: completed.
02
Drugs
Yushuda
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2200065191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065191.